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Background: Psoriasis is a multifactorial, chronic disease of skin affecting 2-3% of the world’s population. Genetic studies
of psoriasis have identified a number of susceptibility genes that are involved in anti-viral immunity. Furthermore,
physiological studies have also found an increase in anti-viral proteins in psoriatic skin. These findings suggest the
presence of an anti-viral state in psoriatic skin. However, the triggers for this anti-viral cascade and its consequences for
host immunity are not known. Endogenous retroviruses have previously been described in many autoimmune diseases
including psoriasis.
Methods: In the present study we examined the humoral immune response against human endogenous retrovirus-K
(HERV-K) proteins and the cutaneous expression levels of multiple HERV-K genes in psoriasis patients and healthy controls.
Results: In psoriatic sera we observed a significant decrease in IgM response against three HERV-K proteins: Env surface
unit (SU), Env transmembrane protein (TM), and Gag capsid (CA) in comparison to sera obtained from blood bank healthy
controls. A decrease in IgG response was also observed against CA. Furthermore, using quantitative RT-PCR we observed
a decrease in the expression of HERV-K Env, Gag, Pol and Rec as well as ERV-9 genes in lesional psoriatic skin as compared
to healthy skin.
Conclusions: Together, our results suggest that the pro-inflammatory, anti-viral state in psoriasis is associated with
diminished expression of HERV-K gene transcripts and a concomitant decrease in humoral responses to HERV-K.
Our results indicate that a simple model where continuous, minimally changing HERV-K expression serves as an
antigenic trigger in psoriasis might not be correct and further studies are needed to decipher the possible relationship
between psoriasis and HERVs.
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Psoriasis is a common T-cell mediated autoimmune dis-
ease, affecting 2-3% of the world’s population. Genetic
studies of psoriasis have identified over 40 susceptibility
loci [1-3]. One of the interesting findings of these studies
is the observation that many of these genetic variants in-
volve genes that are known to play important roles in
anti-viral defense mechanisms. Notable among these are
IL28RA, IFIH1, DDX58 [3], and RNF114 [4]. IL28RA* Correspondence: GuptaR@derm.ucsf.edu
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unless otherwise stated.codes for the alpha subunit of IL-28 receptor and forms
a complex with the IL-10 receptor, IL10RB. This recep-
tor complex interacts with three closely related virus-
induced cytokines, IL28A, IL28B and IL29 and plays role
in antiviral defense [5]. IFIH1 has been known to play
an important role in sensing viral nucleic acids and in
activation of anti-viral immune responses. DDX58 en-
codes the RIG-I innate antiviral receptor, which recog-
nizes cytosolic double stranded RNA. The exact function
of RNF114 is not known but its paralog RNF125 is in-
volved in ubiquitination of the innate anti-viral recep-
tors, RIG-I and MDA5 [6]. Additionally, certain HLA
alleles associated with psoriasis such as HLA-B*57 andtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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trol of HIV-1 [7,8].
Physiological studies on psoriatic skin have also indi-
cated a role of anti-viral restriction factors or anti-viral
proteins (AVP) in psoriasis. A previous study has found
that AVPs such as MX1, BST2, ISG15 and OAS2 are
strongly elevated in the skin of psoriatic patients in com-
parison to healthy controls [9]. The authors further ob-
served that IL29 might be responsible for the antiviral
milieu in psoriasis as its expression correlated with AVP
levels. Recently, we have performed whole transcriptome
analysis of psoriasis skin and found that antiviral restric-
tion factors are strongly upregulated in psoriatic skin and
not in atopic dermatitis skin (manuscript in preparation).
Altogether, these results suggest that psoriasis patients
might have a strong cutaneous anti-viral immunity. How-
ever, the inciting factors and consequences of this anti-
viral immunity are not known.
Possible triggers for psoriasis have been attributed to
drugs [10] or pathogens such as bacteria and possibly
virus [11]. Human endogenous retroviruses (HERVs)
might play a role in triggering these anti-viral immune
responses, since the role of HERVs in the pathogenesis
of autoimmune diseases has generated considerable
interest [12]. HERVs exist as proviruses in the human
genome and consist of 5-10 kb of sequence encoding
three genes, Gag, Pol and Env, flanked on both sides by
long terminal repeats (LTR), which are 300-1200 nucleo-
tides in length. They are estimated to have integrated
into human genome starting 30-40 million years ago and
as recently as 150,000 years ago [13]. Most HERVs have
undergone significant mutational changes and are not
thought to encode infectious virus, although there may
be exceptions [14]. There are many families of HERVs
but the most recent and widespread entrants into the
human genome belong to the HERV-K family of en-
dogenous retrovirus (HML-2, human MMTV like fam-
ily), which are believed to have integrated into the
human genome 200,000 to 5 million years ago [15,16].
Studies also report that it as one of the most transcrip-
tionally active HERV in human genome [17,18].
Expression of HERV-K is known to be up-regulated in
several diseases, including breast cancer, ovarian cancer,
during HIV infection, and rheumatoid arthritis (RA),
where an increase in viral mRNA and viral load of
HERV-K was observed in active disease [19-23]. However,
functional consequences of this expression are not known.
It has been proposed that HERVs can trigger immune re-
sponses directly by acting as super-antigens, by encoding
auto-antigens or by mimicking the self-proteins. Indeed,
antibodies against HERVs are often observed in the sera
of patients, resulting from an increase of transcriptional
and translational activity [24,25]. Alternatively, HERVs
could indirectly affect immune responses by influencingexpression of genes, regulating immune responses, or
facilitating tolerance.
The first evidence of role of HERVs in psoriasis came
from the observation of retrovirus like particles from the
skin of psoriasis patients [26]. Bessis et al. [27] observed
that most of psoriasis patients showed positive immuno-
fluorescence staining for HERV-E transmembrane enve-
lope glycoprotein while only 15% of normal skin samples
were positive. Furthermore, using a pan-retroviral detec-
tion system, it was observed that endogenous retroviral se-
quences for HERV-K, HERV-E and ERV-9 are expressed
both in psoriatic and in normal skin [28]. These authors
then used specific primers for ERV-9 and saw a significant
increased expression in lesional skin compared to con-
trols, but did not report quantitative measurements on
HERV-K or HERV-E. However, the biological significance
and the level of expression of HERV in psoriasis are not
entirely known.
In the present study, we examined the humoral im-
mune response against proteins coded by HERV-K Gag
and Env gene in psoriasis patients and controls. We fur-
ther used a sensitive approach, quantitative reverse tran-
scription PCR (RT-qPCR), to measure the expression
level of a comprehensive panel of HERV-K sequences
(gag, env, pol and rec) in lesional and non-lesional skin
from psoriatic patients compared to normal skin from
healthy controls.Methods
Patient enrollment and sample collection
Fourteen subjects with chronic, plaque psoriasis with af-
fected body surface area > 10% and not on systemic
medications were recruited from the UCSF Dermatology
Department. All subjects provided written, informed
consent for study participation under the approval of the
local Institutional Review Boards. Five-millimeter punch
biopsies were taken from the edge of a psoriatic plaque
as well as from non-lesional skin located greater than
2 cm from any affected area. Twenty seven normal skin
samples were obtained from healthy control surgical dis-
card specimens. Skin samples were stored in RNALater
(Ambion) at −80°C. Samples were mechanically homoge-
nized using a Bio-Gen Pro 200 homogenizer and total
RNA was extracted using the RNeasy mini kit (Qiagen)
and a proteinase K digestion step was included in the
manufacturer’s protocol. RNA was treated with DNAse
at two steps, first during the extraction and secondly be-
fore converting RNA to cDNA. The quantity and quality
of the RNA was assessed using a Nanodrop 8000 and in
some cases by using an Agilent 2100 Bioanalyzer. For
the ELISA, healthy donor sera were obtained from the
Blood Center of the Pacific of San Francisco (n = 16).
Psoriasis sera were obtained from subjects with chronic,
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Recombinant proteins and peptides
HERV-K (HML-2) envelope transmemembrane protein
(recTM), surface unit (recSU) and Gag capsid (recCA) re-
combinant proteins were obtained as previously described
[24,29]. Furthermore, a set of 164 overlapping “15-mer”
HERV-K (HML-2) Gag peptides (JPT Peptide Technolo-
gies, Berlin, Germany) were used to comprehensively map
the antibody response. 5 positive peptides were identified
as reacting with healthy donor sera: 16-KRIGKELKQ
AGRKGN (Matrix), 58-GYPGMPPAPQGRAPY (p15),
81-GVKQYGPNSPYMRTL (Capsid), 117-SIADEKARKVIV
ELM (Capsid) and 137-KCYNCGQIGHLKKNC (Nucleo-
capsid, NC).
ELISA
ELISA was adapted from Michaud et al. [24]. Briefly, 96
microtiter wells plate (Nunc-Immuno Plate MaxiSorp
Surface) were coated for 1 hour at 37°C with peptides at
10 μg/ml in phosphate buffer saline (PBS) or overnight
at 4°C with recombinant protein (GeneArt) at 5 μg/ml
in PBS. Plates were then washed 3 times with 200 μL of
PBS/0.05%-Tween 20 and blocked with 100 μL of block-
ing buffer [PBS/2.5%-Bovine Serum Albumin (BSA)] at
room temperature (RT). The samples were diluted in
blocking buffer and incubated 2 h at RT in duplicates.
Plates were then washed 3 times with 200 μL of PBS/
0.05%-Tween 20. An anti-human IgG or anti-human
IgM horseradish peroxidase (HRP)-conjugated second-
ary antibody was diluted (1:1000 for IgG and 1:2000 for
IgM) in blocking buffer and incubated at RT for 1 hour.
Plates were then washed 6 times with 200 μL of PBS/
0.05%-Tween 20 and incubated for 10 minutes with
100 μL of TMB (3,3′,5,5′-tetramethylbenzidine, Invitro-
gen). Addition of 50 μL H2SO4 2 M stopped the reac-
tion. The plates were read at 450 nm and 690 nm for
the background on a plate reader. Background from
450 nm uncoated wells and PBS-BSA as negative con-
trols was subtracted from the mean absorbance of the
coated wells.
Quantitative RT-PCR
Expression of HERV-K (Gag, Pol, Env and Rec) and ERV-
9 were studied using previous published and validated
primer sequences [30,31] (Additional file 1). DNAse treat-
ment, cDNA conversion and PCR for all samples were
done by Genomic Analysis Core Facility, Helen Diller
Family Comprehensive Cancer Center, UCSF. Real time
PCR was performed using the TaqMan chemistry on the
ABI Prism 7900HT instrument (Life Technologies). PCR
was conducted in triplicate with 20 μL reaction volumes
of 1X Taqman buffer (1X Applied Biosystems PCR buffer,20% glycerol, 2.5% gelatin, 60nM Rox as a passive refer-
ence), 5.5 mM MgCl2, 0.5 mM each primer, 0.2 μM each
deoxynucleotide triphosphate (dNTP), 200 nM probe, and
0.025 unit/μL AmpliTaq Gold (Applied Biosystems) with
5 ng cDNA. A large master mix of the above-mentioned
components (minus the primers, probe, and cDNA) was
made for each experiment and aliquoted into individual
tubes, one for each cDNA sample. cDNA was then added
to the aliquoted master mix. The master mix with cDNA
was aliquoted into a 384-well plate. The primers and
probes were mixed together and added to the master mix
and cDNA in the 384-well plate. PCR was conducted
using the following cycle parameters: 1 cycle of 95° for
10 minutes and 40 cycles of 95° for 15 seconds, 60° for
1 minute. Analysis was carried out using the SDS software
(version 2.3) supplied with the ABI 7900HT to determine
the Cq values of each reaction. Cq values were determined
for three test and three reference reactions in each sample,
averaged, and subtracted to obtain the ΔCq [ΔCq = Cq
(target) – Cq (reference)]. PCR efficiencies were measured
for all custom assays and were greater than or equal to
90%.
RPLP0 (Taqman assay: Hs04189669_g1, Life Technolo-
gies) was used as the reference gene. The relative mRNA
expression was measured as 2^(−ΔCq)*100 according to
Schimttgen and Livak [32]. All the genes were compared
independently.
Statistical analyses
Humoral responses assayed by ELISA were compared
between groups using the two-tailed Mann-Whitney
tests. The relative mRNA was compared among the dif-
ferent groups using Anova Kruskal-Wallis and Dunn’s
multiple comparison tests. All tests were conducted
using GraphPad Prism, version 6.00 (GraphPad Software,
San Diego, CA), with the statistical significance of the
findings set at a p value of less than 0.05.
Results
Antibody responses to HERV-K proteins in psoriasis and
control sera
We first investigated the humoral immune response
against HERV-K in the sera of psoriasis patients and
healthy controls. For these experiments, we examined
the antibody responses against the two envelope sub-
units encoded by the Env gene: the transmembrane pro-
tein (Env-recTM) and surface unit (Env-recSU), and the
capsid encoded by Gag (Gag-recCA).
In healthy donors, we observed a basal level of IgM
reacting with both Env-recSU and Gag-recCA while the
response against Env-recTM was low. Interestingly, the
IgM response was significantly decreased in psoriatic
sera against all three recombinant proteins (Figure 1A).
In healthy donor sera, the IgG response against HERV-K
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est response against Gag-recCA was seen. This latter is
significantly decreased in psoriasis patients in compari-
son to controls while the responses against Env-recSU
and Env-recTM were not significantly modified in psor-
iasis patients (Figure 1B). Furthermore, we also exam-
ined IgG responses against five Gag peptides that we
have previously identified as reacting with healthy donor
sera among a set of 164 overlapping “15-mer” HERV-KFigure 1 Measurement of anti-HERV-K (HML-2) Env and Gag
antibodies in psoriatic patients. Graphs represent the detection of
IgM against recombinant Env transmembrane (recTM), recombinant
Env surface unit (recSU) and recombinant Gag capsid (recCA)
proteins (A) or IgG against recTM, recSU and recCA (B) and
individual HERV-K (HML-2) Gag peptides (C) in healthy donor (white
dots, n = 16) and psoriatic (black dot, n = 28) sera. The figure shows
the representative results of three independent experiments. In all
graphs data represent mean and standard error of mean (SEM). A p
value <0.05 was considered as significant. *p < 0.05,
**p < 0.01, ***p < 0.001.(HML-2) Gag peptides (see Methods). We identified a
significant increase of IgG in psoriatic sera against
peptide 137, belonging to the HERV-K (HML-2) nucleo-
capsid, while the four other peptides did not display any
significant difference in antibody levels (Figure 1C).
Together, these results demonstrated a significant re-
duction in IgM and IgG anti-HERV-K (HML-2) anti-
bodies for most of the epitopes tested in psoriasis
patients, suggesting the possibility that these proteins
might be transcribed at a lower level in patients with
psoriasis.Differential expression of HERV genes in psoriatic and
normal skin
To investigate whether HERV antibody titers might be
influenced by HERV expression levels, we performed
RT-qPCR analysis on RNA obtained from lesional and
non-lesional skin from a different set of psoriasis pa-
tients. We initially screened our samples for expression
of 13 HERV genes representing several HERV families
(HERV-K Gag, HERV-K Pol, HERV-K Env, ERV-9,
HERV-K Rec, HERV-E4.1, HERV-R, HERV-H, HERV-L,
HERV-W, HML-2, HML-4, HML-5) using published de-
generate primer/probe sequences [30,31]. For our screen,
we pooled cDNA from 11 lesional and 4 non-lesional
samples and performed efficiency testing using five-fold
serial dilutions of the cDNA pool. Of the 13 genes
screened, only 5 (HERV-K Gag, HERV-K Pol, HERV-K
Env, HERV-K Rec, ERV-9) were efficient. The other 8
genes were either not efficient or did not meet the min-
imal threshold for expression in our cDNA pool and thus
were not further evaluated.
We evaluated expression of the remaining five genes
(HERV-K Gag, HERV-K Pol, HERV-K Env, HERV-K Rec,
ERV-9) by qPCR in skin biopsies from 14 psoriasis pa-
tients (non-lesional and lesional) and 27 healthy controls.
We used RPLP0 as an endogenous control, as it has been
validated as a reference gene in prior studies of psoriasis
[33-36]. Furthermore, we confirmed that RPLP0 is not dif-
ferentially expressed between psoriasis and controls by
performing RNA sequencing on an independent set of
psoriasis patients (18 lesional and 16 healthy skin con-
trols), with a differential expression q-value of 0.123 (not
significant).
We found that psoriasis patients and controls both
showed detectable expression of HERV genes but that
lesional skin from psoriasis patients showed a significant
decrease in expression of each gene as compared to skin
from healthy controls (Figure 2A to E). There was also a
significant decrease in expression between psoriasis non-
lesional skin and control for the HERV-K Rec and ERV-
9 genes. The HERV-K Env, Gag and Pol genes also
showed a trend towards decreased expression in non-
Figure 2 Relative HERV mRNA expression of Env, Gag, Pol and Rec in psoriatic patients. Graphs represent the expression of Env (A), Gag
(B), Pol (C), Rec (D) and ERV-9 (E) mRNA relative to that of reference gene RPLP0. All the experiments were done in triplicate. In all graphs data
represent mean and SEM. Black bar represents lesional skin (n = 14), light grey bar indicates non-lesional skin (n = 14) and dark grey bar indicates
healthy control skin (n = 27). A p value <0.05 was considered as significant. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. In case of Rec, high
Cq values were obtained.
Gupta et al. Journal of Translational Medicine 2014, 12:256 Page 5 of 8
http://www.translational-medicine.com/content/12/1/256lesional skin as compared to control skin, with p values
of 0.08, 0.05, and 0.4, respectively.
Discussion
Previous studies on HERVs indicate an association with
several autoimmune diseases, cancers and even several
infectious diseases. Some studies have also reported an
association of HERVs and psoriasis [27,28]. However,
these studies did not quantify the level of expression of
HERV-K, which is known to have entered into human
genome very recently and which is also believed to
most functionally active of all endogenous retroviruses.
To understand the association of HERV-K expression
with psoriasis, we first examined the humoral immuneresponse against HERV-K recombinant proteins in sera
of psoriasis patients and controls. We observed that
psoriasis patients showed a significant decrease in IgM
responses against HERV-K Env-recTM, Env-recSU, and
Gag-recCA. Coherent with this observation, the IgG re-
sponse against those proteins were either not modified
or decreased in psoriasis patients.
When we measured the responses against the more im-
munogenic linear peptide epitopes of HERV-K (HML-2)
Gag (see Methods), we detected an increase in antibody
titer against a single linear epitope belonging to the
nucleocapsid (Gag 137). This epitope is also the most
immunogenic in healthy donors. Although we detected a
decreased antibody response against HERV-K recombinant
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Gag 137, discordant antibody responses against HERV-
K (HML-2) have previously been reported. For instance,
although being derived from a single transcript, SU and
TM [37,38] show discordant transcriptional regulation
in HIV-1 patients resulting in different specific humoral
responses [24]. We can thus speculate that, as observed
during HIV-1 infection, HERV-K (HML-2) transcrip-
tional activity of different transcripts might be differen-
tially modified during psoriasis. Alternatively, high
specificity of B-cell receptor or MHC Class II binding
to a particular epitope may lead to heightened antibody
responses. Of note, we have previously shown that
psoriasis patients have stronger antibody responses
against HERV-K dUTPase recombinant protein com-
pared to healthy controls [39]. It is noteworthy that
only peptide 137 elicited responses in either controls or
patients, and this 15mer has a 12/15 amino acid iden-
tity with the amino acid positions 74–88 of the pre-
dicted CaO19.10692 protein from Candida albicans,
which is known to be more frequent in psoriasis pa-
tients [40] and could potentially cause cross reaction.
We further analyzed the expression of various HERV-
families in a pooled set of cDNAs derived from 11
lesional and 4 non-lesional skin samples. However, we
only observed expression of HERV-K genes (Env, Gag,
Pol and Rec) and ERV-9. We then compared the expres-
sion level of HERV-K (Env, Gag, Pol and Rec) and ERV-
9 genes in a larger set of patients, 14 pairs of lesional
and non-lesional skin biopsies from psoriasis patients
and 27 biopsies from healthy controls. In accordance
with our ELISA findings, we observed a decreased ex-
pression of all HERV-K genes tested as well as ERV-9 in
comparison to healthy controls.
Regarding the relationship of our ELISA results and
our RT-qPCR results, there was a partial overlap be-
tween mRNA sequences examined by RT-qPCR and the
proteins used for antibody testing. Our primer/probe set
for the Env gene amplifies a part of SU gene, thus the
decrease in Env expression seen by RT-qPCR directly
correlates to the decrease in IgG and IgM responses
against SU by ELISA. In contrast, our primer/probes for
Gag amplify part of NC and thus do not directly correl-
ate with the decreased antibody response seen here in
case of CA. These results might be verified by either
using primer/probes that amplify CA or using recombin-
ant NC for analysis of antibody responses.
Taken together, our results demonstrate that decreased
expression of HERV-K Gag and Env in psoriasis patients
correlate with a decreased antibody response against these
proteins. Although the decreased expression levels are not
necessarily causal for the decreased antibody responses,
the relationship is suggestive. Interestingly, a similar de-
crease in ERV expression was observed in a recent studyon systemic lupus erythematosus (SLE) using RNA se-
quencing to characterize SLE transcriptome [41]. Thus,
certain inflammatory diseases may be associated with sup-
pression of HERV transcription.
There are several possible mechanisms to explain the
observed decreased expression of HERV-K in psoriasis. It
has been observed that global control of HERV expression
can occur by heritable changes in gene expression without
any change in underlying DNA sequences. These include
alternation of DNA methylation or histone modification
[42]. Past studies have reported that ERV transcription
can be controlled by the methylation state of genomic
DNA [43]. Furthermore, it has been shown previously that
treatment of cells with agents promoting demethylation of
genomic DNA could result in ERV induction [44]. All
these findings have suggested that methylation of genomic
DNA could be a way to control and regulate HERVs.
Methylation studies done on psoriasis skin samples have
observed differentially methylated regions (DMRs) cover-
ing a large part of the genome [45,46]. Furthermore,
Zhang et al. [45] observed that the number of hyper-
methylated DMRs was considerably higher than that of
hypomethylated DMRs in lesional samples form psoriasis
patients. Whether these hypermethylated sites correspond
to the genomic locations of HERVs would be interesting
to determine.
Another mechanism that might affect HERV expression
is RNA degradation of HERVs at the level of post-
transcription. In fact, recent studies done in this regard in-
dicate that control of HERVs can occur both at the level
of transcript repression by methylation and RNA degrad-
ation at post-transcription and these two mechanisms can
be interrelated. A third possibility is RNA interference. It
has been speculated that dsRNA derived from retrotran-
sposons and other retroelements may induce both tran-
script degradation and DNA methylation by using RNA
interference (RNAi) pathways [43] and this can be driven
by small interfering (siRNA) and Piwi-interacting RNA.
Furthermore, these small RNAs can also help in targeting
of repeats for DNA methylation and other chromatin
modifications mechanisms.
Our present results contrast the results from Bessis et
al., and Moles et al., [27,28] in that they found increased
HERV expression and we have found decreased HERV ex-
pression. However, Bessis et al. only focused on HERV-E,
and as mentioned earlier not all HERVs will be expressed
in the same manner and this may account for a difference
between HERV-E and HERV-K expression. Moles et al.
did examine HERV-K sequences, but only measured ERV-
9. Even so, we did find ERV-9 with a lower expression
level in psoriasis patients, whereas they found a higher
level of expression. More studies are needed to explain
this discrepancy, but our ERV-9 data is consistent with
our HERV-K results.
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In summary, we have shown that psoriasis patients show
a decrease in antibody response to HERV-K proteins as
compared to healthy controls. Furthermore, we also ob-
served a decrease in expression of HERV-K genes Env,
Gag, Pol and Rec and ERV-9 in psoriasis skin as com-
pared to healthy skin. The reasons for the unexpected,
low levels of HERV expression in psoriatic lesions are
unclear and might be in part a consequence of anti-viral
defense mechanisms. Whether these are triggered by
HERV expression, expression of other antigens, and/or
antigen independent mechanisms pose interesting ques-
tions for future study. Suppression of HERV-K expres-
sion across the genome may also indicate the possibility
that the inflammatory state of psoriasis is associated
with epigenetic changes leading to the observed de-
crease. However, further studies are warranted to ex-
plore this hypothesis.
Study limitations
A limitation of this study is the moderate sample size
examined. Some degree of variability was observed in
mRNA expression across different genes. Independent
replication of our findings in other cohorts is warranted.
Additional file
Additional file 1: Primer/probe sequences of HERV genes tested in
the study.
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